GlassScriptPhysician profile
Clayton E Bredlau
NPI 1124010335
$5,370.75
in general payments reported to CMS, 2019-2025
32 companies · $605 in 2025
The $605 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $635 · 2021: $953 · 2022: $890 · 2023: $649 · 2024: $688 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,942.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $705.75 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $618.48 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $611.83 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $489.75 | 2019-2024 | Farxiga, Wainua |
| Amgen INC. | $362.39 | 2019-2025 | Repatha, Repatha |
| Abiomed | $302.36 | 2019-2022 | |
| Boston Scientific Corporation | $297.04 | 2019-2023 | Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.52 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $216.29 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $201.42 | 2021-2023 | Verquvo |
| Alnylam Pharmaceuticals INC. | $152.03 | 2022-2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $142.27 | 2023-2024 | Uptravi, Opsumit |
| Abbott Laboratories | $125.15 | 2019-2021 | |
| Philips North America LLC | $124.46 | 2022-2025 | Event |
| Sanofi-Aventis U.S. LLC | $115.85 | 2019-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $97.14 | 2019-2023 | Xarelto |
| Kestra Medical Technology Services, INC. | $95.14 | 2022-2023 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $69.57 | 2019-2023 | Evkeeza |
| Shockwave Medical, INC | $63.18 | 2025 | |
| Medtronic Vascular, INC. | $52.57 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.93 | 2021-2022 | |
| Cardiovascular Systems INC. | $31.56 | 2020 | |
| Vital Connect, INC | $24.88 | 2025 | Vitalpatch Rtm |
| Edwards Lifesciences Corporation | $23.61 | 2020 | |
| Novo Nordisk INC | $22.03 | 2022 | |
| Daiichi Sankyo INC. | $21.91 | 2023 | Injectafer |
| Coala Life INC | $19.16 | 2020 | |
| Roche Diagnostics Corporation | $19.03 | 2019 | |
| Amarin Pharma, INC. | $18.78 | 2019 | |
| Preventice Services, LLC | $15.41 | 2021 | |
| Bardy Diagnostics, INC. | $15.00 | 2020 | |
| Glaxosmithkline, LLC. | $14.26 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clayton Bredlau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.